Bristol Myers Squibb Highlights Hematology Programs at ASH 2026
The company said its CELMoD programs are advancing across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS. The body is truncated.
The company said its CELMoD programs are advancing across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS. The body is truncated.